about
AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancerTargeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients.BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatmentA nation-wide multicenter retrospective study of the epidemiological, pathological and clinical characteristics of breast cancer in situ in Chinese women in 1999 - 2008.Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer.A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells.miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer.Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer.ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells.Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly.Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer.Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients.The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis.Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models
P50
Q33667940-27747CA4-2282-48F5-9806-2987123C9110Q33815074-3DF43B67-D6F9-4DF6-AE81-9E432A394452Q33998169-3EE753B3-056A-4D80-AC2E-CBFD5D1D12DBQ34584872-5B6AEB3B-783A-4AAC-97FA-5D1D4076BC5AQ34611755-F3C03BD4-0A00-4E45-8698-8A02590ECF68Q34632169-95C9BC8B-4AB5-43AC-BEAF-A1E5BF64244DQ35053869-F48E5BC5-0181-4A8C-AB46-2F31D7FA1834Q36063546-387EACF8-0F4C-4A9E-A1D8-7E05D5468490Q37381467-F8EB6AA7-182A-4701-9076-9DA9BB6C837CQ38715916-8369C335-F125-4311-8E12-D22CF8D6067BQ38936839-76F8971F-3C18-4DC1-86D1-8FAB97EDCCE1Q40134202-9E140594-B527-4B66-A195-DABC892DF383Q41674321-49925ECA-0104-4C51-8D9D-6E8E528A57A7Q47105806-80DE5909-BC53-4ED2-A3B6-144BDC287CA6Q47139128-D20DE3D3-1684-4651-8DFE-6FF5C6ACA3F9Q47790044-A921F6C3-F702-4336-BD42-6FC8E56C7044Q48097821-B4DFF20A-33D4-4EEF-ABB5-02EDDF9D1455Q55036428-44D2C991-990A-4AAC-9071-D179226BABB9Q55288835-8C71ADA1-79BC-476C-B82D-50BD99E0537BQ80572869-7488D120-BD2D-4DCC-BA07-EB621CA22B1A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Xiaoming Xie
@ast
Xiaoming Xie
@en
Xiaoming Xie
@es
Xiaoming Xie
@nl
type
label
Xiaoming Xie
@ast
Xiaoming Xie
@en
Xiaoming Xie
@es
Xiaoming Xie
@nl
prefLabel
Xiaoming Xie
@ast
Xiaoming Xie
@en
Xiaoming Xie
@es
Xiaoming Xie
@nl
P106
P31
P496
0000-0003-0687-4238